RxDoctor Payments DataLook up a doctor →

John Nardandrea, MD

Family Medicine · Ocala, FLNPI 1871572016

Payments from drug & device makers

$30,777,345in general payments, 2019–2025

Across 1,862 payments — averaging $16,529 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$14.7M
  • Eisai Inc.$14M
  • Genentech, Inc.$530K
  • E.r. Squibb & Sons, L.L.C.$492K
  • Novo Nordisk AS$472K
  • Amgen$314K
  • plus $219K from 26 others
$53,660in research payments, 2019–2025

Across 13 payments — averaging $4127.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$54K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$30,777,345 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$122,823
Medicare patients
312
Services billed
9,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →